EMR Messaging Woes (4.11.2025)
Dr. Jack Cush reviews the news, journal reports and regulatory approvals from this past week on RheumNow.com
Read Article
43 days to the Lupus Congress 2025 in Toronto 🦋...see you soon!
Abstract Sessions, Poster Tour Presentations, Plenary Sessions, Scientific Sessions, Debate Sessions, Patient Sessions, Fishbowl Discussion, and GALA DINNER on May 23!!!
@LupusCongress https://t.co/MaWjyofnIz
Zahi Touma, MD, PhD @ZahiTouma( View Tweet )
Should Lupus Nephritis Receive PJP Prophylaxis?
A current review article suggests that the need for Pneumocystis jirovecii pneumonia (PJP) prophylaxis in patients with systemic lupus erythematosus (SLE) and lupus nephritis will need to be individualized based on therapies and risk factors.
There are no clear guidelines
Read Article
185 children with SLE (cSLE) were analyze for long-term outcomes. 38 (20.54%) had serositis. Pts w/ serositis were younger, had more Dz activity, acomorbidities, & mortality. Having both serositis and ESRD increased risk of poor 20 Yr survival. https://t.co/fw8wcuS48E https://t.co/LgS3Sxy7gd
Dr. John Cush @RheumNow( View Tweet )
185 children with SLE (cSLE) were analyze for long-term outcomes. 38 (20.54%) had serositis. Pts w/ serositis were younger, had more Dz activity, acomorbidities, & mortality. Having both serositis and ESRD increased risk of poor 20 Yr survival. https://t.co/tnYgg6MNXp https://t.co/zJor1oTFfD
Dr. John Cush @RheumNow( View Tweet )
📢 Federal funding for lupus research and the Lupus Research Program within the Department of Defense hang in the balance as Congress debates spending priorities.
🔬 Investing in lupus research – and all medical research – is one of the wisest investments we can make. That’s why https://t.co/OgWo5z0fMB
Lupus Research @LupusResearch( View Tweet )
Systematic review 21 studies showed potential of RTX with IVIg in autoimmune Dz - 10 studies on pemphigus (85 pts) - all Positive outcomes except 1 paraneoplastic pemphigus. Infections (eg, P. jirovecii pneumonia) seen in 3. 11 studies (24 pts) Rx'd neuropathies, CND lupus& https://t.co/o0RRUBIqmS
Dr. John Cush @RheumNow( View Tweet )
✅ IF YOU ARE LIVING WITH #LUPUS, you can now try #SLAKE, the ONLINE DIGITAL research tool for assessing your ESSENTIAL KNOWLEDGE about #SLE in English, German, Arabic, Spanish, Chinese, Français, Hindi, Indonesian, Dutch, etc... using the following LINK: https://t.co/nSCdBBMEcx https://t.co/PBAPkGynjP
Links:
Laurent ARNAUD @Lupusreference( View Tweet )
Rheums! Have a rheumatology question or case for Dr.Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/VkPL7thzo8 https://t.co/h85iF6tIVk
Dr. John Cush @RheumNow( View Tweet )
#Thrombocytopenia is common in #antiphospholipid syndrome (APS), and is likely associated with more severe disease. Although the pathophysiology underlying thrombocytopenia in APS has yet to be definitively revealed, mechanisms that play a role (at least in subsets of patients) https://t.co/pUXmb1irbw
Alberto Giraldo @alb_giraldo( View Tweet )
Full read Overview of the effects of Menopause and Estrogen on autoimmune disorders https://t.co/NpVPrnPT6x https://t.co/wt9f5D7WXL
Dr. John Cush @RheumNow( View Tweet )
Post hoc analysis of 5 ph III Belimumab RCTs (BLISS, etc, N=3086) on skin outcomes BILAG & SLEDAI-2K), BEL was superior to PBO (mcBILAG OR: 1.29; mcSLEDAI-2K OR: 1.37). Also if SLEDAI ≥10 & dsDNA+ pts. BEL prevented skin flares (HR 0.70) https://t.co/p1MVVf97Go https://t.co/qwWUyegpyi
Dr. John Cush @RheumNow( View Tweet )
Autoimmune Disease Impact Report
Integrated Benefit Institute, a nonprofit independent research organization, has published its 2025 Autoimmune Disease Impact Report, which examines the health and productivity impacts of five prevalent and costly autoimmune conditions: rheumatoid arthritis, multiple sclerosis,
Read Article
Mizoribine Effective in Lupus Nephritis
A randomized clinical trial has shown that oral mizoribine, a common immunosuppressant in Japan, was noninferior to intravenous cyclophosphamide (CTX) as induction therapy in patients with active lupus nephritis.
https://t.co/OWnGly4TUX https://t.co/zbPPH1n4lU
Dr. John Cush @RheumNow( View Tweet )
ERA, APPs, & Alpha GAL (3.21.2025)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. Listen in for 2 new case questions - Ask Cush Anything.
Read Article
Mizoribine Effective in Lupus Nephritis
A randomized clinical trial has shown that oral mizoribine, a common immunosuppressant in Japan, was noninferior to intravenous cyclophosphamide (CTX) as induction therapy in patients with active lupus nephritis.
https://t.co/OS3yaJlEm7 https://t.co/1YcyfarF09
Dr. John Cush @RheumNow( View Tweet )
Congress Passes Fiscal Year 2025 Funding for Lupus Programs, including
- $10 million Natl Lupus Patient Registry at CDC
- $2 million Natl Lupus Training, Outreach, CTE Program
- $47.08 billion for the National Institutes of Health SLE prgs https://t.co/BCs3lGdrXK https://t.co/58PkKG9ay6
Dr. John Cush @RheumNow( View Tweet )
Mizoribine Effective in Lupus Nephritis
A randomized clinical trial has shown that oral mizoribine, a common immunosuppressant in Japan, was noninferior to intravenous cyclophosphamide (CTX) as induction therapy in patients with active lupus nephritis.
Read Article
Available the first time: https://t.co/4UQlqwujiR 2025 On Demand!
On Demand gives you access to all lectures, Q & A panels, and STEP talks, and all speaker slides and handouts — all packed with insights you won’t find anywhere else.
Non-CME, practical, and finally here.… https://t.co/qZb8OKjPpw https://t.co/Exr8u6QkNc
Links:
Dr. John Cush @RheumNow( View Tweet )
2024 Rheumatology Year in Review
2024 was a year of surprising new growth in technology, with the expansion of new therapeutic options for many patients and clinicians. While these many advances offer new hope, they are countered by disappointments and gapping unmet needs in rheumatology. Below is my top 10 list
Read Article
Polypharmacy (>=5Rx) studied in 81 RA & 30 SLE pts. Polypharmacy incr at 2 yrs ~44% to ~73%. Med adherence >85%. Polypharmacy NOT assoc w/ Dz activity in SLE, but in RA did correlate w/ better DAS28CRP score at one year https://t.co/Jw05DIrBym https://t.co/pLIoDvPj8i
Dr. John Cush @RheumNow( View Tweet )
Early Hydroxychloroquine Slows Cutaneous Lupus Progression
A prospective study of patients with limited cutaneous lupus erythematosus (CLE) shows that early introduction of hydroxychloroquine (HCQ) may prevent progression to systemic lupus erythematosus (SLE).… https://t.co/evsvf2GQiL https://t.co/J0Zl35FEHz
Dr. John Cush @RheumNow( View Tweet )
Full read review of Hydryoxychloroquine -its pharmacology, MOA (eg, blocking TLR 7 & 9), Dz specific efficacy and adverse effects https://t.co/N7XVbfnsfi https://t.co/yjKwcfugOJ
Dr. John Cush @RheumNow( View Tweet )
Bubble Trouble - When Bullous Lupus Bursts onto the SLE Scene
Presentation by Dr. Alana Haussmann at the Rheumatology Winter Clinical Symposia - Feb 2025
https://t.co/N4u4AUbdqH https://t.co/PotKfpOkH7
Dr. John Cush @RheumNow( View Tweet )
Available the first time: https://t.co/4UQlqwujiR 2025 On Demand!
On Demand gives you access to all lectures, Q & A panels, and STEP talks, and all speaker slides and handouts — all packed with insights you won’t find anywhere else.
Non-CME, practical, and finally here.… https://t.co/MHFUWb3az1 https://t.co/cqzZG40Xp5
Links:
Dr. John Cush @RheumNow( View Tweet )
Recent Blogs
